PER 0.00% 7.5¢ percheron therapeutics limited

Ann: Quarterly Update and Appendix 4C, page-4

  1. 3,231 Posts.
    lightbulb Created with Sketch. 267
    Some point extracted from today’s ann that should make the market (hopefully regardless diamond’s effect)) bit more confident:

    1- Upon commencement of the Company’s pivotal trial of ATL1102 in Europe, Dr Price’s responsibilities will also include pharmacovigilance oversight, adverse event reporting and clinical safety monitoring
    ***announcing something like that in my view it looks agreement with EMA for 2b is given for granted.***

    2- Following the recently reported positive clinical trial results in the Phase II clinical trial of ATL1102, the Company is actively exploring clinical development opportunities where inflammation plays a key role in disease progression.
    ATL1102 was previously shown to be highly effective in reducing MS inflammatory brain lesions in a Phase IIa clinical trial in Relapsing Remitting -MS patients.
    ***also here management sound due to results sound very confident to explore applications ***

    Now we need the much waited announcement referring DMD final report/results...
    Last edited by imperatore: 21/04/20
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
7.5¢
Change
0.000(0.00%)
Mkt cap ! $67.61M
Open High Low Value Volume
7.3¢ 7.5¢ 7.1¢ $52.15K 724.6K

Buyers (Bids)

No. Vol. Price($)
1 10000 7.1¢
 

Sellers (Offers)

Price($) Vol. No.
7.5¢ 8095 1
View Market Depth
Last trade - 16.10pm 29/07/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.